Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Loxo Oncology, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $41.4 million SEC-registered common stock…
Anacor $5.2 billion acquisition by Pfizer
Davis Polk is advising Anacor Pharmaceuticals, Inc. on its approximately $5.2 billion acquisition by Pfizer Inc. The…
AbbVie Inc. Offering of $7.8 Billion Senior Notes
Davis Polk advised the representatives of the underwriters, in connection with an SEC-registered offering by AbbVie Inc…
Davis Polk Advises Verisk Analytics on the Sale of Its Health Care Services Business to Veritas Capital
Davis Polk is advising Verisk Analytics, Inc. in connection with the $820 million sale of Verisk’s health care services…
Aeglea BioTherapeutics, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $54.8 million…
Davis Polk Advises Anacor Pharmaceuticals, Inc. on Its $287.5 Million Convertible Senior Notes Offering and Related Capped Call Transactions
Davis Polk advised Anacor Pharmaceuticals, Inc. in connection with its offering of $287.5 million aggregate principal amount…
Corvus Pharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in the $70.5 million…
Davis Polk Advises Hypermarcas on Debt Tender Offer
Davis Polk advised Hypermarcas S.A. in connection with its cash tender offer to purchase any and all of its outstanding $312…
NuVasive, Inc. $650 Million Notes Offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NuVasive, Inc. (“NuVasive”) of $650…
Pfizer Inc. $5 Billion Accelerated Share Repurchase
Davis Polk advised the counterparty in connection with an accelerated share repurchase transaction entered into between the…